Ann: Viralytics to Present at 2017 SITC Annual Meeting, page-55

CAPRA findings (Conclusion) looks pretty good, especially for the Stage IV M1c patients, 64% BORR...

"At present No DLT’s have been observed in the first 26 patients receiving the combination treatment.

• Overall, adverse events have generally been low-grade constitutional symptoms related to CVA21 and standard pembrolizumab-related side effects. At present only two Grade 3 adverse events (hepatic toxicity and keratoacanthoma) related to pembrolizumab have been observed.

• CVA21-pembrolizumab combination therapy was associated with clinical benefit in treated patients.

• Preliminary Best Overall Response Rate (BORR) of 61.0% (14/23 pts) and 4/23 pts with Stable Disease.


• In patients with stage IV M1c disease a BORR of 64% (7/11 pts).

• Preliminary observations have revealed durable reductions in a number of injected and noninjected visceral/non-visceral lesions, with a number of patients displaying evidence of postinjection systemic exposure to CVA21."